What Curatis does

Curatis is a Swiss specialty pharmaceutical company, publicly listed on the Swiss exchange (swx:CURN) and headquartered in Liestal, that operates two complementary businesses: a distribution arm and a development arm. The distribution business acquires, licenses, distributes, and promotes orphan and specialty disease medicines in Switzerland that have been developed and brought to market by third-party pharmaceutical companies, with exclusive distribution rights for more than 40 products spanning opioids, antidotes, oncology supportive care, and rare-disease therapies. The development business targets compounds with pre-existing safety and clinical efficacy data to accelerate development at lower risk and capital intensity, with a pipeline of four candidates: corticorelin (C-PTBE-01) for peritumoral brain edema (FDA-validated pivotal study design, September 2025), C-AM-01 for severe migraine with aura, C-MOH-01 for medication overuse headache, and C-FI-01 for fibrotic or inflammatory orphan diseases.

Revenue is generated through product distribution in Switzerland and milestone/royalty payments from licensing deals, most notably an exclusive Japan agreement with Neupharma (March 2026) covering corticorelin, worth up to CHF 83.5 million in upfront and milestone payments plus up to 20% royalties on future Japanese sales. Reported 2025 revenue of CHF 10.8 million grew 57% versus 2024, with 13% organic growth, and management guides to approximately CHF 15 million in 2026 (~40% growth) and a break-even target for the same year. The customer base is Swiss specialist healthcare professionals and hospitals served indirectly through the distribution business, with no named enterprise customer concentration disclosed. Expansion signals include planned European footprint growth into Germany, France, the UK, and Italy, and the Neupharma partnership extending commercial reach into Japan.

Name

Curatis

Legal name

Curatis Holding AG / Curatis AG

Website

https://curatis.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

1–10 employees

Short description

Curatis is a Swiss specialty pharmaceutical company that acquires, licenses, distributes, and promotes over 40 orphan and specialty disease medicines in Switzerland while developing a proprietary pipeline, including corticorelin for peritumoral brain edema, targeting high unmet medical needs.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)

Keywords

• Specialty pharmaceuticals
• Orphan drug distribution
• Rare disease medicines
• Pharmaceutical pipeline development
• Drug licensing services

Headquarters

HQ city

Liestal

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Product Distribution Business: Distribution business for orphan disease and specialty care medicines: Curatis acquires, licenses, distributes, and promotes medicines for the treatment and/or prevention of orphan and specialty diseases in Switzerland that have been developed and brought to market by third party pharmaceutical companies. The company has exclusive distribution rights for more than 40 different products in Switzerland.
2. Pipeline Development and Licensing: Development business generates revenue through milestone payments and royalties from licensing agreements. Curatis signed an exclusive licensing and development agreement with Neupharma for corticorelin in Japan worth up to CHF 83.5 million plus royalties of up to 20% on future sales.

Go-to-market motion2 records

Distribution channels3 records

Core offering

Curatis acquires, licenses, distributes, and promotes orphan and specialty disease medicines in Switzerland under exclusive distribution rights for more than 40 products. In parallel, it operates a development business identifying compounds with existing safety and clinical efficacy data to advance novel orphan and specialty care therapies (corticorelin/C-PTBE-01, C-AM-01, C-MOH-01, C-FI-01) toward regulatory approval and commercialization, either directly or via licensing.

Product overview

Curatis is a Swiss specialty pharmaceutical company with two business areas: a distribution business for orphan disease and specialty care medicines, and a development business for novel orphan and specialty care drugs. The company distributes over 40 products in Switzerland including specialty care drugs, orphan drugs, and antidotes such as Actiq, Effentora (opioids for breakthrough pain), Cyanokit (for cyanide poisoning), DigiFab (for digoxin toxicity), Cuprior (for Wilson's disease), and elmiron (for bladder pain syndrome). The development pipeline includes four investigational drugs: Corticorelin (C-PTBE-01) for peritumoral brain edema (in pivotal stage), C-AM-01 for migraine prevention, C-MOH-01 for medication overuse headache, and C-FI-01 for fibrotic/inflammatory orphan diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• Distribution of orphan and specialty care medicines in Switzerland (portfolio of 40+ exclusive products) End-to-end Swiss distribution franchise covering registration, pricing, reimbursement, and promotion of more than 40 orphan and specialty disease medicines licensed from third-party pharmaceutical companies, for sale to Swiss specialist healthcare providers, hospitals, and specialty pharmacies.
• Actiq (fentanyl citrate) Opioid medication distributed in Switzerland by Curatis for the treatment of breakthrough pain in cancer patients.
• Effentora (fentanyl buccal) Opioid medication distributed in Switzerland by Curatis for the treatment of breakthrough pain in cancer patients.
• Cyanokit (Hydroxocobalamin) Antidote for cyanide poisoning distributed in Switzerland by Curatis.
• DigiFab (Digoxin Immune FAB) Antidote for digoxin toxicity distributed in Switzerland by Curatis.
• Cuprior (Trientine) Treatment for Wilson's disease, a rare genetic disorder causing copper accumulation, distributed in Switzerland by Curatis.
• elmiron (Pentosan Polysulfate) Treatment for bladder pain syndrome/interstitial cystitis distributed in Switzerland by Curatis.
• Corticorelin (C-PTBE-01) Proprietary pipeline candidate developed by Curatis for the treatment of peritumoral brain edema; currently advancing toward a pivotal clinical study with FDA validation of the development plan.
• C-AM-01 Proprietary pipeline candidate developed by Curatis for the prevention of severe migraine with aura; currently advancing toward a clinical Phase IIb study.
• C-MOH-01 Proprietary pipeline candidate developed by Curatis for the treatment and prevention of medication overuse headache; currently advancing toward a clinical Phase IIb study.
• C-FI-01 Proprietary pipeline candidate developed by Curatis targeting fibrotic or inflammatory orphan and ultra-orphan diseases; currently advancing toward clinical proof-of-concept.

Quantifiable outcome

• Revenue growth of 57% in 2025 to CHF 10.8 million from CHF 9.5 million in 2024
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Neupharma Co., Ltd.coreStrategic or Co-development Partner · 1 March 2026Curatis signed an exclusive licensing and development agreement with Neupharma for corticorelin (C-PTBE-01) to treat peritumoral brain edema in Japan. Neupharma receives exclusive rights to develop and commercialize the therapy in Japan, financing and conducting a pivotal clinical trial to support Japanese regulatory approval. Curatis will receive upfront and milestone payments totalling up to CHF 83.5 million, plus royalties of up to 20% on future Japanese sales. Neupharma plans to meet Japan's PMDA in mid-2026 to discuss requirements for a registration-enabling study expected to commence in 2027.
• Phoenix Labs (Ireland)coreChannel Partner/ Reseller/ Distributor · 1 October 2025Curatis expanded its distribution business with Phoenix Labs through a new distribution contract to distribute four products in Switzerland starting from October 2025. These products generated approximately CHF 5 million in revenues in Switzerland in 2024 and are expected to add up to CHF 5m in additional annual revenues.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curatis